Artificial Intelligence + Care Coach Intervention

Sponsor
Yale University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05352399
Collaborator
(none)
55
1
24

Study Details

Study Description

Brief Summary

The purpose of this research study is to develop and test an artificial intelligence intervention for emergency department (ED) discharge care transitions experienced by caregivers of older adults with cognitive impairment.

Condition or Disease Intervention/Treatment Phase
  • Other: NeuViCare application
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
55 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Artificial Intelligence + Care Coach Intervention for Persons Living With Dementia and Caregivers
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention (NeuViCare AI)

An anticipated 55 participants will be part of the Intervention arm participants and will engage with NeuViCare AI, including all variations of its 5 components described further below.

Other: NeuViCare application
Intervention arm participants will engage with NeuViCare AI, including all variations of its 5 components: 1) NeuViCare Planner - enables review of ordered tests and external resources recommended by the care provider; 2) NeuViCare Task-Support Service - provides context-sensitive, personalized text-based assistance to help patients' complete care plan captured in the NeuViCare Planner; 3) NeuViCare Resource Advisor - presents trusted, unbiased advice to locate nearby resources listed within their care plan; 4) NeuViCare Advisor - educates and trains Persons Living With Dementia (PLWD) and their care partners at the moment of need; and 5) NeuViCare Community Hub - a safe virtual space which enables care partners to interact with other peer care partners to gain their experiential knowledge and emotional support.

Outcome Measures

Primary Outcome Measures

  1. Intervention Appropriateness Measure [Day 30]

    Appropriateness is defined as the perceived fit, relevance, or compatibility of the innovation for a given setting or consumer, and/or perceived fit of the innovation to address a particular issue or problem. The measure consists of 4 questions, with an overall score range of 4-20 (higher scores suggest increased appropriateness). Administration time is 1-2 minutes. Measured by survey.

  2. Feasibility of Intervention Measure [Day 30]

    Feasibility is defined as the extent to which a new innovation can be successfully used or carried out within a given setting. The measure consists of 4 questions, with an overall score range of 4-20 (higher scores suggest increased feasibility). Administration time is 1-2 minutes. Measured by survey.

  3. Acceptability of Intervention Measure [Day 30]

    Acceptability is defined as the perception that a given innovation is agreeable, palatable, or satisfactory. The measure consists of 4 questions, with an overall score range of 4-20 (higher scores suggest increased acceptability). Administration time is 1-2 minutes. Measured by survey.

  4. System Usability Scale [Day 30]

    Usability encapsulates several aspects including subjective component assessments of effectiveness, efficiency, and satisfaction. The System Usability Scale consists of 10 questions on effectiveness, efficiency, and satisfcation, with an overall score range of 10-50 (higher scores suggest increased usability). Administration time is 3-5 minutes. Measured by survey.

Secondary Outcome Measures

  1. Dementia Knowledge Assessment Scale [Day 30]

    The Dementia Knowledge Assessment Scale is a reliable and valid measure of dementia knowledge for health professionals and members of the general public that is capable of elucidating knowledge characteristics across four coherent domains: 1) Causes and Characteristics, 2) Communication and Behaviour, 3) Care Considerations, and 4) Risks and Health Promotion. Statements are true/false for the respondent to answer with scores ranging from 0-21. Administration time is approximately 10-15 minutes. Measured by survey.

  2. Zarit Caregiver Burden Scale [Day 30]

    The Zarit Caregiver Burden Scale consists of 22 items rated on a 5-point Likert scale that ranges from 0 (never) to 4 (nearly always) with the sum of scores ranging between 0-88. Higher scores indicate greater burden. Administration time is approximately 10-15 minutes. Measured by survey.

  3. General Self-Efficacy Scale [Day 30]

    The General Self-Efficacy Scale is used to evaluate the coping ability of daily living. The measure is 10 items with overall scores ranging from 10-40, with higher scores representing greater self-efficacy. Administration time is approximately 3-5 minutes. Measured by survey.

  4. Emergency Department revisits [Day 30]

    Repeat visit to the ED by electronic health record, supplemented with self-report survey to identify those not with the institution's EDs.

  5. Hospitalizations [Day 30]

    Hospitalizations by electronic health record, supplemented with self-report survey to identify those not with the institution's hospitals.

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • age ≥65 years with a diagnosis of dementia within the electronic health record OR new cognitive impairment identified during an ED visit

  • be fluent in English or Spanish

  • discharge after an ED visit

  • possession of a smart device (either a phone, tablet, or computer) that has internet access to utilize and interact with NeuViCare AI services

Exclusion Criteria:
  • evidence of delirium, by the 4-AT screening tool

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Yale University

Investigators

  • Principal Investigator: Cameron Gettel, Yale School of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT05352399
Other Study ID Numbers:
  • 2000032226
First Posted:
Apr 28, 2022
Last Update Posted:
Aug 15, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 15, 2022